Aviceda Therapeutics
Overview
Aviceda Therapeutics is a clinical-stage biotechnology company focusing on developing innovative immunomodulators using a proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform. Founded by Mohamed Genead, Derek Kunimoto, and others in 2018, the company is based in Cambridge, Massachusetts. It has raised notable funding, most recently closing a $207.5 million Series C round in January 2025. Aviceda's lead product, AVD-104, is progressing through clinical trials targeting geographic atrophy and other ophthalmic conditions.
Recent Developments
- January 2025: Aviceda Therapeutics closed a $207.5 million Series C financing round. This funding round was co-led by Omega Funds and TCGX, with significant investments from Enavate Sciences, Jeito Capital, and others. The proceeds will primarily support the ongoing Phase 2b/3 and upcoming Phase 3 clinical trials for AVD-104 in the treatment of geographic atrophy secondary to age-related macular degeneration. The trial results are expected in the second half of 2025.
- September 2024: Aviceda completed enrollment for its Phase 2b SIGLEC study, comparing AVD-104 with avacincaptad pegol in geographic atrophy patients. This trial involves around 300 participants, and the 12-month data are anticipated for the later part of 2025.
- Early 2024: The Phase 2a SIGLEC trial results for AVD-104 demonstrated positive safety profiles and efficacy in reducing GA lesion growth.
- 2019-2023: Aviceda kept progressing in developing its HALOS nanotechnology platform, with a pipeline expanding into ophthalmology, immunology, oncology, and more.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2018 |
| Headquarters | Cambridge, MA |
| Founders | Mohamed Genead, Derek Kunimoto |
| Revenue | Not publicly disclosed |
| Profits | Not publicly disclosed |
| Key Investors | Omega Funds, TCGX, Enavate Sciences, Jeito Capital |
| Industry | Biotechnology |
| Number of Employees | 11-50 |
Early History
Aviceda Therapeutics was founded in 2018, driven by the vision of addressing unmet needs in chronic inflammatory diseases through innovative biotechnology solutions. Utilizing its HALOS nanotechnology platform, Aviceda aims to develop cutting-edge glyco-immuno therapeutics. The company's early focus was on harnessing glycan-based therapies to modulate the immune system, a strategy that led to the development of its flagship drug, AVD-104, for age-related macular degeneration. Founders, with backgrounds in ophthalmology and immunology, recognized the potential of this novel approach to treat complex diseases.
Company Profile and Achievements
Aviceda Therapeutics is renowned for its work in developing a pipeline that includes innovative therapies for various chronic inflammation-associated diseases. Its major focus is on ocular diseases, using the HALOS platform to create nanoparticles that modulate immune responses effectively.
- 2018: Company founded.
- 2022-2023: Development of the HALOS nanotechnology platform expanded, laying groundwork for advanced immunomodulatory therapies.
- 2023: Positive early-phase clinical results for AVD-104.
- 2025: Secured $207.5 million Series C funding to advance clinical trials for AVD-104.
Current Operations and Market Position
Aviceda's current operations center around the advancement of AVD-104, heralded for its potential in treating geographic atrophy. The biotechnology firm is keenly focused on completing pivotal studies that will confirm its therapeutic efficacy and safety. Aviceda operates in a fiercely competitive biotech market but retains a unique position due to its sophisticated technology platform and focus on ophthalmology. This strategy positions Aviceda as a promising player in the fight against debilitating ocular conditions. The HALOS platform's versatility offers expansion opportunities beyond ophthalmology.
Aviceda Therapeutics Products
Aviceda's primary product, AVD-104, is a clinical-stage ophthalmic candidate designed to treat geographic atrophy secondary to age-related macular degeneration. It works by modulating critical inflammatory and complement pathways, proving promising in early trials. Besides ophthalmology, Aviceda's pipeline targets diseases across immunology, oncology, and neurology, leveraging their novel glycan-coated nanoparticle technologies.
Aviceda Therapeutics Careers
As a growing company, Aviceda provides a dynamic workplace for professionals passionate about biotechnology's future. Interested candidates are encouraged to explore opportunities across many roles, particularly in clinical development and regulatory affairs, supporting its expanding research initiatives.
Conclusion
Aviceda Therapeutics is indicative of a new wave of biotech solutions in targeting complex immune-related diseases through specialized nanotechnology platforms. With AVD-104, the company is positioned to alter treatment paradigms within the ophthalmology sector. Continued investment and strategic expansion into broader medical applications underscore Aviceda's potential to impact future healthcare landscapes significantly. As Aviceda's clinical trials advance, there is a promise of innovative therapies revolutionizing immune modulation treatments.